NEW YORK (GenomeWeb) – Myriad Genetics today announced that it has partnered with Quanterix to create immunoassay services based on Quanterix's Simoa platform.
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, will offer Simoa assay services for the study of inflammatory and autoimmune diseases. Quanterix's Simoa technology uses single molecule measurement to detect protein biomarkers in blood samples. Myriad RBM has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 and tumor necrosis factor alpha, the firm said in a statement.
"The Simoa platform is an exciting new tool that is 100 to 1,000 times more sensitive than conventional tests for blood-based protein biomarkers and will open up new avenues of clinical research," said Myriad RBM President Ralph McDade. "Simoa will significantly accelerate biomedical discoveries by providing researchers with valuable insights into both the underlying mechanisms of disease and the safety and efficacy of pharmaceuticals."
Financial and other details of the partnership were not disclosed.
Last month researchers at Tufts University published a proof-of-concept study on a Simoa-based Dengue fever host response test.